Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.230
+0.100 (8.85%)
At close: Aug 22, 2025, 4:00 PM
1.190
-0.040 (-3.25%)
After-hours: Aug 22, 2025, 6:18 PM EDT
Coherus Oncology Employees
Coherus Oncology had 228 employees as of December 31, 2024. The number of employees decreased by 78 or -25.49% compared to the previous year.
Employees
228
Change (1Y)
-78
Growth (1Y)
-25.49%
Revenue / Employee
$1,193,899
Profits / Employee
$788,382
Market Cap
142.96M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 228 | -78 | -25.49% |
Dec 31, 2023 | 306 | -53 | -14.76% |
Dec 31, 2022 | 359 | 27 | 8.13% |
Dec 31, 2021 | 332 | 15 | 4.73% |
Dec 31, 2020 | 317 | 26 | 8.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CHRS News
- 15 days ago - Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 23 days ago - Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 3 months ago - Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - GlobeNewsWire
- 4 months ago - Coherus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 - GlobeNewsWire